 |
May 10, 2013 |
For Investors/IR Library: Consolidated Financial Report for the 3 Months Ended March 31, 2013 |
|
April 11, 2013 |
For Investors/IR Library: Consolidated Financial Report for the Year Ended December 31, 2012 |
|
March 4, 2013 |
AnGes Group Receives FDA Approval of a Revised SPA for Phase III Clinical Trial for Collategene®, a Drug for Ischemic Disease Treatment |
|
January 9, 2013 |
Announcement Regarding Execution of Management Rationalization |
|
December 27, 2012 |
Announcement of Transfer of Shares in a Consolidated Subsidiary |
|
December 13, 2012 |
The Industry-academia Joint R&D Project on “Oral DDS Nucleic Acid Drug Using PLGA Nanoparticle Technology” Receives Technology Prize at the Autumn Annual Meeting and Symposium of the Society of Powder Technology, Japan (SPTJ) |
|
November 16, 2012 |
New Research Findings on Functional Peptide “COSMEPEPTINR” Reported at Society of Cerebral-Cardio-Vascular Anti-Aging 2012 |
|
October 29, 2012 |
For Investors/IR Library: Consolidated Financial Report for the Nine Months Ended September 30, 2012 |
|
October 24, 2012 |
AnGes Enters into the Definitive Agreement with Mitsubishi Tanabe Pharma for Exclusive Marketing Rights of CollategeneR in the United States |
|
October 1, 2012 |
New Medical Use Patent for HGF Granted in Japan for Lymphedema |
|
September 20, 2012: |
First Patient Enrollment in the Clinical Trial of NF-κB Decoy Oligo Coated PTA Balloon Catheter for Hemodialysis Shunts
- Development of a Novel Effective Medical Device for Suppressing Restenosis of Blood Vessels - |
|
August 17, 2012: |
Long-Term Data of Japanese Phase I/II Trial of Collategene (DNA Plasmid with HGF Gene) Published in a Medical Journal
- Gene Therapy Clinical Research in Peripheral Arterial Disease at Osaka University - |
|
August 3, 2012: |
For Investors/IR Library: Consolidated Financial Report for 6 Months Ended June 30, 2012 |
|
July 30, 2012: |
AnGes MG Submits an IND Application for Collategene (HGF DNA Plasmid)
- Initiation of the World’s First Clinical Trial on Gene Therapy for Lymphedema - |
|
July 2, 2012: |
Mitsubishi Tanabe Pharma and AnGes Conclude Basic Agreement
for Exclusive Marketing Rights of CollategeneR in the United States |
|
June 28, 2012: |
Ishihara Sangyo, AnGes MG and Subsidiary GenomIdea Enter into a Letter of Intent for the Transfer of the HVJ-E Business |
|
May 21, 2012: |
Introduction of Shareholder Special Benefit Plan |
|
May 16, 2012: |
Collaboration with Morishita Jintan regarding New Formulation Development for Oral Vaccines using Seamless Capsule Technology |
|
May 8, 2012: |
For Investors/IR Library: Consolidated Financial Report for the 3 Months Ended March 31, 2012 |
|
April 11, 2012: |
Medical-Use Patent for NF-kB Decoy Oligo Granted in Japan
- Intended for Degenerative Disc Disease, Lumbago, etc. - |
|
March 29, 2012: |
Notification of Appointment of A Representative Director |
|
March 28, 2012: |
Commencement of Clinical Trial on NF-κB Decoy Oligo Coated PTA Balloon Catheter for Hemodialysis Shunts
- Development of a Novel Effective Medical Device for Suppressing Restenosis of Blood Vessels - |
|
March 5, 2012: |
Superior Angiogenic Activity of HGF over bFGF or VEGF Published in a Medical Journal
- Better Target for Angiogenic Gene Therapy - |
|
February 25, 2012: |
For Investors/IR Library: Consolidated Financial Report for the Year Ended December 31, 2011 |
|
February 13, 2012: |
Regarding Results from an Exploratory Clinical Study on a Therapeutic Vaccine for Cervical Precancerous Lesion (CIN Therapeutic Vaccine) |
|
January 26, 2012: |
Medikit and AnGes MG Enter into Development, Manufacturing and Distribution Agreement
- Development of a Drug Coated Balloon Catheter, Effective in Preventing Vascular Restenosis - |
|
January 25, 2012: |
An Academic Research using “Collategene,” a Treatment Agent for Ischemic Disease was Adopted for a Grant in the UK
- A Research on HGF Gene Therapy for Venous Graft Disease by Bristol University - |
